• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 17, 2014

View Archived Issues

Abbvie calls the whole Shire thing off; faces $1.6B break-up fee

DUBLIN – Abbvie Inc. is walking away from its $55 billion takeover of Shire plc and, potentially, into a whole pile of trouble. Read More

J&J pledges up to $817M for Aduro cancer therapies

Johnson & Johnson unit Janssen Biotech Inc. is committing $30 million up front, plus up to $787 million in milestones to Aduro Biotech Inc. for an exclusive global license to a lung cancer treatment based on Aduro's Listeria-based immunotherapy platform. Read More

Brazil's Anvisa suspends Meningitec vaccine

The surveillance agency of Brazil's Ministry of Health (Anvisa) suspended on Thursday the distribution and commercialization of the meningococcal serogroup C conjugate vaccine Meningitec, following a global recall by its owner Nuron Biotech Inc., of Exton, Pa. Read More

Adaptimmune's solid tumor immunotherapy data early but promising

LONDON – Adaptimmune Ltd. has released the first positive clinical data of its second-generation T-cell immunotherapy in a solid tumor, reporting four of five patients with advanced synovial sarcoma have responded to the treatment. Read More

'Seed' sprouts: Women gain ground in biotech, says Canaan VC partner

The industry has reached a tipping point with regard to women in higher-ranking positions, said Wende Hutton, general partner with venture capital (VC) firm Canaan Partners. Read More

Gut has unexpected relationship to eating disorders

The social pressures leading to eating disorders are well known. But the disorder also has a biological component. Genetic studies have uncovered variants that are associated with the risk of developing anorexia, and twin studies suggest they may be a larger contributor to who will become anorexic or bulimic than social pressures. Read More

Efforts to curb Ebola epidemic focusing on vaccine development

With nearly 10,000 confirmed cases of Ebola and the World Health Organization (WHO) expecting up to another 10,000 new Ebola infections per week in West Africa, the need for a vaccine has never been more apparent. Read More

Financings

Esperion Therapeutics Inc., of Ann Arbor, Mich., said it priced an underwritten public offering of 4.2 million shares of its common stock at $20 each for expected gross proceeds of $85 million. Read More

Stock movers

Read More

Other news to note

Batu Biologics Inc., of San Diego, said it signed a license agreement with the Regents of the University of California, gaining exclusive rights to peptide drugs developed at UC San Diego that have been proven to stimulate cancer-killing immune responses. Read More

In the clinic

Pharmacyclics Inc., of Sunnyvale, Calif., said it entered a master clinical drug supply agreement with Roche AG, of Basel, Switzerland, to evaluate safety, tolerability and preliminary efficacy of Imbruvica (ibrutinib), an oral Bruton's tyrosine kinase inhibitor, in combination with Gazyva (obinutuzumab), a CD20-directed antibody, in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Read More

Pharma: Other news to note

Eli Lilly and Co., of Indianapolis, said it plans to conclude production and pursue a sale of one of its three manufacturing facilities in Puerto Rico. The facility, located in Guayama, will remain in operation until the end of 2015. Read More

Pharma: In the clinic

Novartis AG, of Basel, Switzerland, said immunotherapy, CTL019, that was the subject of a study partly funded by the Leukemia & Lymphoma Society (LLS) over the past 22 years and published in the New England Journal of Medicine, showed that 90 percent of children and adults with acute lymphoblastic leukemia (ALL) achieved complete remission after receiving the investigational personalized cellular therapy. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 9, 2025.
  • The Nasdaq Stock Exchange headquarters in New York

    Omada, Caris arrivals continue med-tech IPO hot streak

    BioWorld MedTech
    Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe